Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02061761
Title Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb

diffuse large B-cell lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

chronic lymphocytic leukemia


Nivolumab + Relatlimab


Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.